Elutia Inc Class A (ELUT)

In May 2026, Elutia Inc. announced it would report its first-quarter 2026 financial results on May 14, 2026. Insider trading activity was reported in April 2026. In March 2026, the company's price target was increased by 42.86% to $5.10, and they presented at Sidoti's Small-Cap Virtual Investor Conference. Full-year 2025 earnings were reported, with EPS exceeding expectations but revenues falling short, and a delisting risk was warned. A new risk related to revenue and earnings growth was identified. In October 2025, Elutia closed the $88 million cash sale of its BioEnvelope business to Boston Scientific Corporation. As of April 22, 2026, the stock price was $1.16 per share, a 49.34% decline from the previous year.

Based on the available information, there is no explicit mention or indication of significant demand seasonality for Elutia, Inc.'s products and services.

Elutia, Inc. is a biopharmaceutical company focused on developing and commercializing drug-eluting biomatrix products to improve the compatibility between medical devices and patients. The company's core business revolves around its polymeric nitric oxide platform and drug-eluting biomatrix products used in surgical reconstruction. Elutia operates in two segments: Women's Health and Cardiovascular, with most revenue from Women's Health. Major products include SimpliDerm, ProxiCor, Tyke, and VasCure. CanGaroo and EluPro were sold to Boston Scientific in October 2025. Lead development programs include NXT-41 and NXT-41x, biologic scaffolds combined with local antibiotic delivery.

Elutia, Inc. is headquartered in Gaithersburg, Maryland, and primarily serves the U.S. market. The company is actively pursuing collaborations to support international expansion, selling products directly to hospitals and healthcare facilities through independent sales agents.

Elutia's EluPro product has demonstrated strong market adoption and revenue growth. However, Elutia has a "High Risk" ESG rating as of April 4, 2026, and acknowledges vulnerability to individuals tarnishing its brand and reputation.

Elutia, Inc. has a diverse ownership structure. Institutional investors own 74.03% of the stock, insiders hold 93.56%, retail investors hold 0.00%, venture capital/private equity firms hold 16.4%, and hedge funds hold 21.6%. Major institutional owners include Nantahala Capital Management, LLC, and Vanguard Group Inc. Highcape Capital LP is the largest individual shareholder, owning 44.37% of the company.